Technology ID
TT-0107
Description
Our neuroregenerative technology heralds a new era for treating CNS traumas and degenerative diseases, offering new hope for conditions such as glaucoma, stroke, and spinal injury paralysis. By fostering axonal regeneration and neural circuit repair with small molecule therapies, we’re reshaping CNS healthcare.
Content
Tailored Therapeutics: Our treatments are designed for specific neuron diseases, providing targeted and effective remedies for conditions with limited options
Innovative Advantage: With novel small molecules, our platform stands out for its precision and potential
Commercial Trajectory: Currently in the preclinical trial phase with secured funding, our path to market entry is clear, targeting a sector with a projected value of over $120 billion by 2030
Inventors
Applicable Industries
Potential Application
Technology Focus
TRL